PIK3CB and neoplasm: These studies could include additional preclinical modeling in PIK3CA wild-type estrogen-deprivation-resistant tumor lines to determine whether PIK3CA mutation is necessary in endocrine-resistant tumors to confer PI3K inhibitor sensitivity.